COSTANZO, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 17.943
EU - Europa 2.200
AS - Asia 599
SA - Sud America 13
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 10
AF - Africa 2
Totale 20.778
Nazione #
US - Stati Uniti d'America 17.924
UA - Ucraina 427
CN - Cina 423
DE - Germania 364
SE - Svezia 263
IE - Irlanda 256
IT - Italia 182
PL - Polonia 173
FR - Francia 169
GB - Regno Unito 162
FI - Finlandia 82
KR - Corea 81
RU - Federazione Russa 58
BE - Belgio 24
IN - India 18
CA - Canada 17
JP - Giappone 17
KG - Kirghizistan 11
AU - Australia 10
IL - Israele 10
NL - Olanda 9
EU - Europa 8
SG - Singapore 8
CH - Svizzera 7
UZ - Uzbekistan 7
BR - Brasile 6
HK - Hong Kong 6
ES - Italia 5
CL - Cile 4
PK - Pakistan 4
RO - Romania 4
VN - Vietnam 4
DK - Danimarca 3
GR - Grecia 3
IR - Iran 3
HR - Croazia 2
MX - Messico 2
MY - Malesia 2
NO - Norvegia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
AT - Austria 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
MD - Moldavia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
SC - Seychelles 1
TR - Turchia 1
TW - Taiwan 1
Totale 20.778
Città #
Woodbridge 4.873
Wilmington 3.992
Houston 3.517
Ann Arbor 900
Fairfield 815
Chandler 638
Ashburn 474
Seattle 396
Jacksonville 393
Cambridge 293
Dublin 254
Medford 221
Beijing 185
Dearborn 179
Kraków 170
New York 115
Lawrence 103
Zhengzhou 83
Mülheim 67
San Diego 49
Menlo Park 43
Boardman 42
San Mateo 34
Rome 32
Falls Church 31
Milan 27
Shanghai 25
Brussels 24
Redwood City 21
Saint Petersburg 17
Hefei 16
Mountain View 16
University Park 15
London 13
Jinan 11
Nanjing 11
Norwalk 11
Auburn Hills 10
Kunming 10
Guangzhou 9
Hangzhou 9
Perugia 9
Toronto 9
Nürnberg 8
Pune 8
Verona 8
Saint Louis 7
Changsha 6
Chicago 6
Detroit 6
Wuhan 6
Clearwater 5
Nanchang 5
Shenyang 5
Bern 4
Chengdu 4
Hebei 4
High Wycombe 4
Hounslow 4
Palo Alto 4
São Paulo 4
Trani 4
Amsterdam 3
Berlin 3
Calgary 3
Casarile 3
Chiyoda-ku 3
Cremona 3
Fuzhou 3
Hanoi 3
Los Angeles 3
Madrid 3
Manchester 3
Nijmegen 3
Phoenix 3
Redmond 3
Tappahannock 3
Tokyo 3
Ypsilanti 3
Bangalore 2
Baoding 2
Bethesda 2
Cagliari 2
Chaoyang 2
Chongqing 2
Cosenza 2
Florence 2
Guidonia 2
Helsinki 2
Indiana 2
Islington 2
Kilburn 2
Kuala Lumpur 2
Melbourne 2
Messina 2
Montréal 2
Nanning 2
Neuruppin 2
Padova 2
Prescot 2
Totale 18.357
Nome #
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 456
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis 438
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage 425
Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients 422
Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis 415
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 414
Induction of gene expression via activator protein-1 in the ascorbate protection against UV-induced damage 412
The p53/p63/p73 family of transcription factors: overlapping and distinct functions 411
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 404
Actinic keratosis treated with an immune response modifier: a case report of six patients 402
IL-21 Promotes Skin Recruitment of CD4+ Cells and Drives IFN- -Dependent Epidermal Hyperplasia 402
Ascorbate up-regulates MLH1 (Mut L homologue-1) and p73: Implications for the cellular response to DNA damage 401
Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target 390
Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population 387
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 382
Structure, function and regulation of p63 and p73 380
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage 377
PSORS2 markers are not associated with psoriatic arthritis in the Italian population 377
IL-21 in the pathogenesis and treatment of skin diseases 375
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 374
Herpes simplex virus disrupts NF-kappa B regulation by blocking its recruitment on the I kappa B alpha promoter and directing the factor on viral genes. 366
Pathogenic role of interleukin-21 in psoriasis 364
Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases 360
Induction of neuronal differentiation by p73 in a neuroblastoma cell line 358
Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain 357
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody 353
The tumor suppressor activity of IKK alpha in stratified epithelia is exerted in part via the TGF-beta anti proliferative pathway 353
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 353
Zosteriform metastasis of occult bronchogenic carcinoma 346
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 346
Elementi di dermatologia 337
Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene 325
Zosteriform metastasis of occult bronchogenic carcinoma 324
Two new p73 splice variants, gamma and delta, with different transcriptional activity 318
Efficacy and safety of long-term infliximab therapy in moderate to severe psoriasis and psoriatic arthritis 317
Psoriasis: from pathogenesis to novel therapeutic approaches 313
Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants  and  301
High-dose Intravenous Immunoglobulin for Severe Drug Reactions: Efficacy in Toxic Epidermal Necrolysis 292
Effects of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse model 288
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 282
IL-21, a new player in pathogenesis of psoriasis 274
Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA 261
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study 216
Claudin-1 is a p63 target gene with a crucial role in epithelial development 149
Treasure or artifact: a decade of p63 research speaks for itself 143
Treatment of vitiligo with the 308 nm excimer laser 139
A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias 136
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab 129
p63 and p73 transactivate differentiation gene promoters in human keratinocytes 128
Different applications of monochromatic excimer light in skin diseases 127
308 nm monochromatic excimer light in the treatment of psoriasis 126
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways 125
Moderate and severe plaque psoriasis: Cost-of-illness study in Italy 123
Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides 122
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers 120
Consecutive use of different biological therapies in the treatment of psoriasis [4] 117
A feedback regulatory loop between p63 and Dlx3: implications for epidermal differentiation 117
p63 induces key target genes required for epidermal morphogenesis 116
Safety and efficacy study on etanercept in patients with plaque psoriasis 116
A role of p73 in mitotic exit 114
Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells 114
DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes 112
Regulation of Dlx5 and Dlx6 gene expression by p63 is involved in EEC and SHFM congenital limb defects 112
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience 111
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations 110
NF-κB, IκB Kinase and Interacting Signal Networks in Squamous Cell Carcinomas 106
p73 is regulated by phosphorylation at the G2/M transition 105
Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells 105
Safety and efficacy study on etanercept in patients with plaque psoriasis 105
Homeobox gene Dlx3 is regulated by p63 during ectoderm development: relevance in the pathogenesis of ectodermal dysplasias 102
Cross-talks in the p53 family - Delta Np63 is an anti-apoptotci target for Delta Np73 alpha and p53 gain-of-function mutants 100
deltaEF1 repressor controls selectively p53 family members during differentiation 100
CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappaB subunits on IL-8 and Bcl-xL gene promoters 99
RelA/NF-kappa B recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells 98
Etanercept for the treatment of severe childhood psoriasis [3] 97
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting 95
Pharmacological treatment of androgenetic alopecia.Result of an observational study 95
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 93
Differential regulation of E2F1 apoptotic target genes in response to DNA damage 91
Efficacy and safety of etanercept in psoriasis after switching from other treatments: An observational study 88
Emerging treatments in the management of psoriasis: biological targeting with ustekinumab 86
A p38-dependent pathway regulates DeltaNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes 86
The p73 gene is an anti-tumoral target of the RAR beta/gamma-selective retinoid tazarotene 85
CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappa B subunits on IL-8 and Bcl-xL gene promotors 83
Etanercept reverses downregulation of inhibitor of nuclear factor kappa-B kinase subunit alpha (IKKa) in psoriasis 77
Pharmacogenomics: getting closer to a tailored therapy? 76
Delta Np63 Knockdown Mice: A Mouse Model for AEC Syndrome 75
DNp73 alpha protects myogenic cells from apoptosis 71
Efalizumab 70
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 65
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 64
Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis 60
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis 55
Keratosis punctata palmoplantaris and malignancies: case report 52
Label-free and non-invasive discrimination of HaCaT and melanoma cells in a co-culture model by hyperspectral confocal reflectance microscopy 49
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 48
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis 48
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis 42
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 40
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment 36
Totale 20.901
Categoria #
all - tutte 44.722
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.722


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.571 0 0 0 0 0 0 0 0 0 453 581 537
2019/20205.493 428 373 380 528 445 626 521 529 486 518 295 364
2020/20213.037 287 372 322 354 240 279 352 271 144 117 224 75
2021/20221.147 36 91 111 63 29 116 44 60 83 122 60 332
2022/20231.530 167 132 84 246 136 315 84 75 153 6 97 35
2023/2024417 74 18 29 19 43 140 21 68 3 2 0 0
Totale 21.003